These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer.
    Author: Koliakos G, Chatzivasiliou D, Dimopoulos T, Trachana V, Paschalidou K, Galiamoutsas V, Triantos A, Chitas G, Dimopoulos A, Vlatsas G.
    Journal: Dis Markers; 2000; 16(3-4):143-6. PubMed ID: 11381196.
    Abstract:
    The importance of insulin-like growth factor 1 (IGF-1) in human serum for the early diagnosis of prostate cancer is controversial. The IGF-1/PSA ratio may improve the performance of prostate specific antigen (PSA) as a prostate cancer marker. IGF-1, along with PSA and free PSA concentration, was measured in the serum of 34 patients with prostate cancer and in 131 patients with benign prostatic hyperplasia (BPH). Although IGF-1 concentration did not significantly differ between the groups, PSA/IGF-1 ratio could clearly distinguish the two groups. In patients with cancer but not in patients with BPH, IGF-1 concentration correlated with PSA and free PSA. The values of PSA and free PSA correlated with each other for both groups. Receivers Operating Curve (ROC) analysis indicated a better sensitivity to specificity ratio for PSA/IGF-1 than for PSA or Free/Total (F/T) PSA.
    [Abstract] [Full Text] [Related] [New Search]